阿贝西利联合内分泌治疗应用于HR+/HER2-、淋巴结阳性、高风险早期乳腺癌:评monarchE研究  

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-,Node⁃Positive,High⁃Risk,Early Breast Cancer:Review of monarchE Study

作　　者：许锐 何嘉发 邹佳晨 XU Rui;HE Jia-fa;ZOU Jia-chen(Breast Clinic Center,Guangdong Provincial Hospital of Chinese Medicine,The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510006,China;不详)

机构地区：[1]广东省中医院大学城医院乳腺科,广州中医药大学第二附属医院,广州510006 [2]南方医科大学附属广东省人民医院(广东省医学科学院)乳腺肿瘤科,广州510080

出　　处：《循证医学》2023年第2期74-77,共4页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Johnston SRD,Harbeck N,Hegg R,et al.monarchE Committee Members and Investigators.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+,HER2-,node-positive,high-risk,early breast cancer(monarchE)[J].J Clin Oncol,2020,38(34):3987-3998.

关 键 词：阿贝西利 辅助内分泌治疗 激素受体阳性 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]